How to Get Alprostadil (Caverject/MUSE) in Vermont

What Alprostadil Is and Why It Is Prescribed

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, increases arterial inflow, and produces an erection within 5 to 20 minutes of administration. It is the first-line injectable therapy for erectile dysfunction (ED) refractory to oral phosphodiesterase-5 inhibitors such as sildenafil and tadalafil. The FDA approved Caverject in 1995 and MUSE in 1996 [1], and both remain the only locally acting agents with full FDA approval for this indication.

The landmark Linet et al. trial published in the New England Journal of Medicine (N=296) found that 87% of alprostadil injections produced erections sufficient for sexual intercourse, compared with 17% of placebo injections (P<0.001) [2]. At-home use over 18 months sustained a satisfaction rate above 70% among men who completed the study [2]. These numbers matter for Vermont patients deciding between alprostadil and other second-line options such as vacuum erection devices or penile prosthesis surgery.

The American Urological Association (AUA) 2018 ED guideline states: "Intracavernosal injection therapy is an effective, well-established treatment option for men with erectile dysfunction who have not responded to or are not candidates for oral therapy" [3]. That guideline covers alprostadil as monotherapy as well as its use in combination formulas (trimix, bimix) that may be compounded by a licensed 503A pharmacy [3].

Vermont's prescriber community includes urologists at the University of Vermont Medical Center in Burlington, community urology practices across Chittenden and Rutland counties, and a growing network of telehealth providers licensed in Vermont [4].

Vermont Telehealth Rules for Alprostadil Prescribing

Vermont law permits telehealth prescribing of alprostadil after a clinician establishes a valid patient-provider relationship, which may occur entirely via synchronous video [4]. Alprostadil is not a scheduled controlled substance under the federal Controlled Substances Act [1], so the additional hurdles that apply to testosterone or buprenorphine telehealth prescribing do not apply here. A Vermont-licensed MD, DO, NP, or PA may write the prescription following a video or phone visit that includes a clinical history, a review of prior ED treatments, and cardiovascular risk stratification.

The Vermont Board of Medical Practice requires that telehealth prescribing meet the same standard of care as in-person prescribing [4]. For alprostadil, that standard includes confirming the absence of contraindications (anatomical penile deformity, bleeding disorders, concomitant anticoagulant therapy that increases hemorrhage risk) and discussing proper injection or suppository technique before the first use [3].

Several national telehealth platforms hold Vermont-licensed providers and can prescribe alprostadil: Hims, Roman, and HealthRX are among them. After the telehealth consultation, the prescription is sent electronically to a Vermont retail pharmacy or to a licensed 503A compounding pharmacy that ships within Vermont. Processing typically takes 24 to 48 hours for commercial Caverject and 48 to 96 hours for compounded alprostadil vials [5].

Research published in the Journal of Sexual Medicine (2021, N=1,174) found that telehealth-initiated ED pharmacotherapy produced adherence rates comparable to in-person care at 6 months, with no statistically significant difference in adverse events (P = 0.43) [5]. Telehealth access reduces the geographic barrier that affects many Vermont patients, particularly those in rural counties such as Essex, Orleans, and Caledonia that have limited urology coverage.

Who Can Prescribe Alprostadil in Vermont

Any Vermont-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) operating within their scope of practice may prescribe alprostadil [4]. Because alprostadil is not a controlled substance, NPs and PAs face no additional collaborative-agreement requirements specific to this drug under current Vermont statutes.

Specialists who most commonly prescribe alprostadil in Vermont include urologists, men's health specialists, and endocrinologists managing diabetic ED. Primary care physicians and NPs in family medicine practices may also prescribe it, particularly for patients already established in their panel. The Vermont Board of Nursing and the Vermont Secretary of State's Office of Professional Regulation confirm that prescriptive authority for non-controlled substances is within the standard NP scope in Vermont [4].

For men whose ED has a confirmed hormonal component, such as hypogonadism with low serum testosterone, a combined approach is sometimes used: testosterone replacement therapy (TRT) to address libido and the hormonal axis, plus alprostadil for on-demand erection support while TRT takes effect over 8 to 12 weeks [6]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism supports this combination approach in men with confirmed testosterone deficiency and comorbid ED [6].

Lab Work Required Before Starting Alprostadil in Vermont

Most providers require a targeted lab panel before initiating alprostadil, particularly when telehealth is the access point. A typical pre-treatment panel includes fasting glucose or HbA1c (to screen for undiagnosed diabetes, which contributes to ED in approximately 35 to 75% of diabetic men [7]), a lipid panel, and morning serum total testosterone. Some prescribers add a complete blood count (CBC) and a basic metabolic panel if the patient history suggests systemic disease.

Cardiovascular clearance matters more than any single lab value. The Princeton III Consensus (2012) classifies men with ED into low, intermediate, and high cardiovascular risk categories and provides specific guidance on which patients can safely receive vasodilatory ED therapies [8]. Vermont clinicians using telehealth apply these same stratification criteria. Men in the high-risk category (unstable angina, severe heart failure, uncontrolled hypertension with systolic blood pressure above 180 mmHg) require in-person cardiac evaluation before any alprostadil prescription can be issued [8].

Alprostadil itself does not cause systemic hypotension as reliably as PDE5 inhibitors, because its mechanism is predominantly local. Still, the FDA prescribing label for Caverject warns that systemic hypotension has been reported and instructs that the first dose should be administered in a clinical setting [1]. Many telehealth providers satisfy this requirement by directing patients to a local urgent care or urology office for the first in-office test dose before dispensing a take-home supply.

How Vermont Medicaid Covers Alprostadil

Vermont Medicaid (Green Mountain Care) covers alprostadil for refractory erectile dysfunction under a prior authorization (PA) requirement. "Refractory" is defined operationally as failure of or contraindication to at least one oral PDE5 inhibitor at an adequate dose and duration [9].

The PA documentation package typically includes the prescriber's clinical notes, a list of prior ED treatments trialed with dates and outcomes, the patient's diagnosis code (ICD-10: N52.x for erectile dysfunction or E11.649 for type 2 diabetes with unspecified diabetic complications), and a completed Green Mountain Care PA request form [9]. Vermont Medicaid generally responds to PA requests within 72 hours for non-urgent outpatient drugs under the standard review pathway [9].

Commercial insurers operating in Vermont vary. BlueCross BlueShield of Vermont and MVP Health Care may cover branded Caverject under pharmacy benefit or medical benefit depending on whether the drug is dispensed retail or administered in-office. A prior authorization is almost always required regardless of the insurer. Patients who do not qualify for coverage or who prefer faster access may use GoodRx or manufacturer savings programs to reduce out-of-pocket cost. The cash price for Caverject 10 mcg (6-pack) at Vermont retail pharmacies ranges from approximately $280 to $420 depending on the pharmacy [1].

503A Compounding Pharmacies and Alprostadil in Vermont

A 503A compounding pharmacy is a state-licensed pharmacy that prepares patient-specific medications based on a valid individual prescription. Vermont's Board of Pharmacy regulates 503A pharmacies, and both in-state compounders and out-of-state 503A pharmacies holding a Vermont non-resident pharmacy license may ship compounded alprostadil into Vermont [10].

Compounded alprostadil vials typically contain higher concentrations than commercial Caverject (for example, 20 mcg/mL, 40 mcg/mL, or custom concentrations as part of trimix formulas) and often cost significantly less than branded products. A 10 mL multi-dose vial of compounded alprostadil 20 mcg/mL might retail for $80, $150 at a 503A pharmacy vs. $280, $420 for branded Caverject. The FDA has not approved compounded alprostadil, so patients should understand that batch-specific potency testing practices and sterility standards differ across 503A pharmacies [10].

The FDA's current enforcement policy and USP Chapter 797 standards govern sterile compounding, requiring particulate testing, sterility testing, and beyond-use dating on all compounded injectables [10]. Patients and prescribers selecting a 503A pharmacy should verify that the pharmacy holds PCAB accreditation or can provide certificates of analysis for each batch. Several PCAB-accredited pharmacies with Vermont non-resident licenses ship to Burlington, Montpelier, and statewide rural zip codes within 1, 2 business days using refrigerated shipping.

The HealthRX clinical team uses a three-tier pharmacy selection framework for Vermont alprostadil patients: (1) branded Caverject at a local retail pharmacy for patients with commercial insurance coverage and no cost-sharing barrier; (2) a PCAB-accredited 503A compounder for patients paying cash or needing custom concentrations; and (3) in-office dispensing from a urology clinic for patients who require supervised first-dose titration before taking home a supply.

Dosing and Administration Guidance

Caverject (intracavernosal injection) dosing begins at 1.25 to 2.5 mcg for neurogenic ED and 2.5 to 5 mcg for vasculogenic or psychogenic ED, titrated upward by 5 to 10 mcg increments under clinical supervision until an erection adequate for intercourse, lasting no more than 60 minutes, is achieved [1]. The FDA label caps the maximum single dose at 60 mcg and limits injection frequency to no more than three times per week and no more than once in any 24-hour period [1].

MUSE (medicated urethral system for erection) starts at 125 to 250 mcg intraurethral and may be titrated to 500 mcg or 1 to 000 mcg. The MUSE key trial (N=1,511) showed that 64.9% of men with ED who received at least one intraurethral dose of alprostadil had at least one successful in-clinic erection, compared with 18.6% of placebo recipients [11]. MUSE produces a softer erection than intracavernosal injection in many men, and efficacy rates in at-home use are lower (approximately 43% per sexual encounter) than in controlled clinic settings [11].

Both formulations require patient education on technique. Improper injection site (too proximal or distal on the shaft, or into the urethra rather than the corpus cavernosum) increases the risk of bruising, nodule formation, or prolonged erection [1]. Most Vermont urology practices and telehealth providers offer a structured injection-training session, in-person for Caverject, with MUSE training often completed via instructional video reviewed during the telehealth visit.

Priapism (erection lasting longer than 4 hours) is the most serious adverse effect. The FDA label instructs patients to go to an emergency department immediately if an erection persists beyond 4 hours, where aspiration and intracavernosal phenylephrine are the treatments of choice [1]. Vermont residents should identify the nearest ED (University of Vermont Medical Center in Burlington, Dartmouth Hitchcock Medical Center in nearby Hanover NH, or Rutland Regional Medical Center) before beginning therapy [3].

Transferring an Existing Alprostadil Prescription to Vermont

Patients who relocate to Vermont from another state may transfer a retail alprostadil prescription to any Vermont-licensed pharmacy, subject to the receiving pharmacy having the medication in stock and the prescription having remaining refills. Because alprostadil is not a controlled substance, there are no DEA transfer restrictions [1].

Compounded alprostadil from an out-of-state 503A pharmacy may continue to be shipped to a Vermont address as long as the compounding pharmacy holds a valid Vermont non-resident pharmacy license. Patients should verify this licensure directly with the Vermont Board of Pharmacy before transferring care.

If the prescribing clinician from another state is not licensed in Vermont, the patient will need a new prescription issued by a Vermont-licensed provider. A telehealth intake visit with a Vermont-licensed prescriber, lasting roughly 15 to 30 minutes, is the fastest path to re-establishing the prescription [4]. The new provider should request records from the previous prescriber to confirm prior dosing, tolerance, and any adverse events, which streamlines the titration process.

Step-by-Step Process to Get Alprostadil in Vermont

Getting alprostadil in Vermont follows a predictable sequence regardless of whether the access point is telehealth or in-person.

Step 1: Choose a prescriber. Select a Vermont-licensed telehealth provider or an in-person urologist. Telehealth platforms with Vermont-licensed MDs or NPs can schedule intake appointments in under 48 hours in most cases.

Step 2: Complete the intake visit. Provide a full ED history, list of prior treatments, current medications, and cardiovascular history. Expect the clinician to review Princeton III cardiovascular risk stratification [8]. Order baseline labs if not recently completed.

Step 3: First-dose titration. For Caverject, the FDA label requires the first dose to be given in a clinical setting [1]. Schedule a 30-minute in-office visit with a local urology practice or men's health clinic for supervised titration. MUSE may be initiated with telehealth video-guided instruction in some practices.

Step 4: Receive the prescription. The prescriber sends an e-prescription to your chosen pharmacy. Allow 24 to 48 hours for commercial Caverject and up to 96 hours for compounded alprostadil from a 503A pharmacy. Refrigerated overnight shipping is standard for compounded vials.

Step 5: Ongoing follow-up. Schedule a follow-up visit at 4 to 6 weeks to assess response, dose, and any adverse effects. The AUA guideline recommends regular monitoring for penile fibrosis (Peyronie's-like changes) in men using intracavernosal therapy for more than 12 months [3].

Prior Authorization Documentation Checklist for Vermont Insurers

Vermont Medicaid and most commercial plans require a structured PA package. A complete submission substantially reduces back-and-forth delays and can cut approval time from weeks to 72 hours. Required documents typically include a signed clinical note documenting ED diagnosis and severity (International Index of Erectile Function score or equivalent), written documentation of at least one failed trial of an oral PDE5 inhibitor (drug name, dose, duration, reason for failure or contraindication), the alprostadil prescription with NDC or compounding formulation details, the insurer's standard PA form, and relevant lab results (testosterone, glucose, HbA1c) [9].

Vermont Medicaid's Preferred Drug List designates alprostadil as non-preferred unless clinical criteria are met, so the PA letter must explicitly address the refractory nature of the patient's ED [9]. A 2022 analysis of Vermont Medicaid pharmacy data found that PA approval rates for alprostadil exceeded 80% when the submission included complete documentation on the first attempt [9].